25Aug
Johnson & Johnson Announces Acquisition of Momenta For $6.5 Billion
Johnson and Johnson announced that it has entered into an agreement to acquire Momenta Pharmaceuticals, Inc. for $6.5 billion. The acquisition gives J&J’s Janssen unit full global rights to Momenta’s nipocalimab (M281), an anti-FcRn antibody designed to treat a number of autoantibody-driven disorders, including generalized myasthenia gravis (gMG), warm autoimmune hemolytic anemia (wAIHA), and hemolytic disease of the fetus and newborn (HDFN)....
By:
Goodwin
Related
As part of the New York State Legislature’s push to pass legislation at the end of its 2019 Session...
Read More >
“Fair value” means the value of the shares on a sale between a willing buyer and a willing seller,...
Read More >
A few months ago, Kamala Harris unveiled an ambitious plan to introduce stricter legal measures to f...
Read More >
Seyfarth Synopsis: California Labor Code § 221 states it is “unlawful for any employer to collect o...
Read More >
One - SPACs (special purpose acquisition or "blank cheque" companies) have recently regained promi...
Read More >
In some situations, employers call us to ask about an employee’s request for job modifications that...
Read More >